[Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].
Manuel Barreiro-PérezPablo Pastor PueyoSergio Raposeiras RoubinDolores Montero CorominasAitor UribarriRocío Eiros BachillerJosé Rozado CastañoLuisa García-Cuenllas ÁlvarezLuis Serratosa FernándezFernando DomínguezDomingo Pascual FigalPublished in: Revista espanola de cardiologia (2023)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccines. The high prevalence of COVID-19, vaccination programs expansion, and the appearance of new information regarding myocarditis in these contexts make it necessary to condense the knowledge acquired since the pandemic began. With this aim, the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS), has written this document. It aims to address the diagnosis and treatment of cases of myocarditis-associated SARS-CoV-2 infection or messenger RNA vaccine.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- coronavirus disease
- heart failure
- healthcare
- public health
- health information
- mental health
- risk factors
- climate change
- single cell
- cardiac surgery
- left ventricular
- atrial fibrillation
- social media
- risk assessment
- human health
- nucleic acid
- thoracic surgery
- health promotion
- drug induced